MX385405B - Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. - Google Patents

Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.

Info

Publication number
MX385405B
MX385405B MX2017014084A MX2017014084A MX385405B MX 385405 B MX385405 B MX 385405B MX 2017014084 A MX2017014084 A MX 2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A MX 385405 B MX385405 B MX 385405B
Authority
MX
Mexico
Prior art keywords
eye
vitreous
treat
kinase inhibitor
injectable composition
Prior art date
Application number
MX2017014084A
Other languages
English (en)
Other versions
MX2017014084A (es
Inventor
Paul Ashton
Original Assignee
Eyepoint Pharmaceuticals Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Us Inc filed Critical Eyepoint Pharmaceuticals Us Inc
Publication of MX2017014084A publication Critical patent/MX2017014084A/es
Publication of MX385405B publication Critical patent/MX385405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen composiciones y métodos relacionados con el uso de inhibidores de cinasa para el tratamiento de la degeneración macular y/o la oclusión de la vena retiniana.
MX2017014084A 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. MX385405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (2)

Publication Number Publication Date
MX2017014084A MX2017014084A (es) 2018-06-20
MX385405B true MX385405B (es) 2025-03-18

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014084A MX385405B (es) 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.

Country Status (10)

Country Link
US (1) US20160324836A1 (es)
EP (1) EP3291812B1 (es)
JP (1) JP2018520093A (es)
CN (1) CN107530334A (es)
AU (1) AU2016258001B2 (es)
BR (1) BR112017023762A2 (es)
CA (1) CA2984637A1 (es)
MX (1) MX385405B (es)
RU (1) RU2017137763A (es)
WO (1) WO2016179357A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170094793A (ko) 2014-12-15 2017-08-21 더 존스 홉킨스 유니버시티 수니티닙 제제 및 녹내장의 치료에서의 그의 사용 방법
MX2018005932A (es) 2015-11-12 2019-05-20 Graybug Vision Inc Microparticulas aglomerantes para terapia medica.
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
MX2019013363A (es) 2017-05-10 2020-01-13 Graybug Vision Inc Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica.
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
WO2020250252A1 (en) * 2019-06-11 2020-12-17 Sifi S.P.A. Microemulsion compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
US20140235678A1 (en) * 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
EP2776837A4 (en) * 2011-11-11 2015-05-20 Intellikine Llc COMBINATION OF KINASEINHIBITORS AND THEIR USE
JP2015500343A (ja) * 2011-12-14 2015-01-05 アッヴィ・インコーポレイテッド キナーゼ阻害剤を含有する組成物

Also Published As

Publication number Publication date
EP3291812A1 (en) 2018-03-14
CA2984637A1 (en) 2016-11-10
CN107530334A (zh) 2018-01-02
BR112017023762A2 (pt) 2018-07-31
AU2016258001A1 (en) 2017-11-09
EP3291812B1 (en) 2021-09-01
JP2018520093A (ja) 2018-07-26
RU2017137763A (ru) 2019-06-05
AU2016258001B2 (en) 2020-06-04
US20160324836A1 (en) 2016-11-10
RU2017137763A3 (es) 2019-08-21
WO2016179357A1 (en) 2016-11-10
MX2017014084A (es) 2018-06-20
EP3291812A4 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX385405B (es) Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2024007658A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2021009673A (es) Moduladores de ror-gamma.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal